Jurisdiction

Jurisdiction

This subtopic considers the jurisdiction elements of Regulation (EU) 1215/2012 on jurisdiction and the recognition and enforcement of judgments in civil and commercial matters (recast) (Brussels I (recast)). The precursor to Brussels I (recast) was Regulation (EC) 44/2001 and the two regulations together, with the Brussels Convention, are known as the Brussels Regime. The Brussels regime applies between EU Member States with the exception of Denmark which is party to a separate agreement. On 10 January 2015, Brussels I was repealed in its entirety, subject to transitional provisions. However, given the passage of time jurisdictional issues are no longer determined under Brussels I.

Brussels I (recast)

Practice Notes

•
Brussels I (recast)—application and exclusions considers Brussels I (recast) and what matters it will be applied to, as well as what specific matters that are excluded by are set out in the regulation as being excluded. It sets out transitional arrangements, international requirements and what constitutes civil and commercial matters. It also sets out what is excluded by the regulation and how to deal with state immunity
•
Brussels I (recast)—domicile considers the different articles set out in Brussels I (recast)

To view the latest version of this document and thousands of others like it, sign-in with LexisNexis or register for a free trial.

TAKE A FREE TRIAL

Latest EU Law News

EMA launches AI research priorities survey to inform regulatory focus

The European Medicines Agency (EMA) has launched an EU survey ran by the joint HMA-EMA Network Data Steering Group (NDSG) to identify key research priorities for artificial intelligence (AI) in the development and evaluation of medicines. It aims to gather structured input from stakeholders including the European Medicines Regulatory Network (EMRN), industry, SMEs, patients, consumers, academics and healthcare professionals. Survey feedback will be used to define priority areas that can support safe and effective use of AI in medicine, with the findings to be shared with the broader research community to advance academic and multi-stakeholder research. The survey forms part of the NDSG’s 2025–2028 workplan to optimise data use and leverage AI for better decision-making in medicines regulation. The survey closes on 17 October 2024.

Do not bottle the truth—major soft drinks company commits to correcting its recycling claims under EU law

EU Law analysis: Gabriela de Costa, Georgina Rigg, Aurelija Grubytė and Anna Carter of K&L Gates consider the following-In November 2023, a coalition of consumer protection organisations from across the EU reported several major bottled drinks companies to the European Commission and the Consumer Protection Authorities (CPA Network) for making misleading recycling claims on their bottles. Following the complaint, a global drinks company voluntarily offered to make a series of changes to the recycling claims on its plastic bottles

EMA publishes EU network data strategy following public consultation

The European Medicines Agency (EMA) has published the European Medicines Agencies Network Data Strategy on 3 October 2025, following a public consultation conducted between November and December 2024. The strategy focuses on making more effective use of data hosted by the European medicines regulatory network and aims to ensure data meets high quality standards whilst being appropriately organised, standardised and easily shared among regulators and stakeholders. The document, reference number EMA/128369/2025, is intended to facilitate collaboration and more informed regulatory decision-making across the network. The strategy builds on EMA's existing work in leveraging data including regulatory submissions data, substance and product master data, and real-world data such as electronic health records and patient registry data to support public health decisions in the European Union.

EFPIA blog calls for refinement of EU GLP proposals

The European Federation of Pharmaceutical Industries and Associations (EFPIA) has published a blog welcoming the revision of the EU’s General Pharmaceutical Legislation (GPL), while cautioning that some provisions—such as limited flexibility in using Real-World Evidence and the exclusion of marketing authorisation holders from labelling decisions when data is generated by regulators or third parties—could unintentionally undermine the framework’s effectiveness if not refined.